REGN
Regeneron Pharmaceuticals Inc
796.00$
-0.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +2.1% | -8.4% | +12.8% | +4.9% | +1.8% | -20.1% | +21.4% | +2.1% | +3.5% | -7.2% | +19.0% | – | |
| – | +16.1% | -31.0% | +10.7% | +2.3% | +15.1% | -17.9% | +14.2% | -1.6% | +12.1% | +14.5% | -13.9% | – | |
| – | -0.6% | -3.4% | +13.1% | +5.3% | -0.2% | -20.5% | +22.7% | +2.8% | +2.1% | -11.0% | +26.5% | – | |
| – | +8.3% | +19.5% | -2.5% | +8.5% | +7.4% | -6.0% | +6.9% | +8.8% | +4.4% | +1.2% | -0.8% | – | |
| – | +15.2% | -6.6% | +10.1% | -5.9% | +10.9% | -20.1% | +0.2% | +3.7% | +17.8% | -16.4% | +2.2% | – | |
| – | +9.0% | +11.7% | +1.9% | +2.6% | +9.0% | -11.7% | +4.7% | +6.8% | +9.7% | -5.2% | +0.0% | – | |
| – | -13.2% | -28.5% | +42.3% | +10.3% | -16.0% | -40.2% | +82.4% | -4.9% | -14.3% | -26.9% | +121.0% | – | |
| – | +2.8% | -12.0% | -8.1% | -6.8% | -23.9% | -17.1% | -58.6% | +436.1% | -36.8% | +5.7% | -14.7% | – | |
| – | +3.3% | -38.9% | +132.4% | -8.3% | -35.8% | -5.5% | +67.8% | +16.1% | -40.8% | -20.4% | +83.8% | – | |
| – | -111.7% | – | – | -22.2% | -73.5% | +138.4% | +32.0% | +138.6% | -34.4% | -47.8% | +122.0% | – | |
| – | +15.1% | -37.7% | +98.4% | -6.4% | -31.5% | -11.9% | +72.1% | +4.9% | -42.2% | -13.9% | +78.3% | – | |
| – | +3.6% | -35.0% | +112.3% | -7.7% | -32.8% | -5.0% | +59.3% | +15.8% | -37.4% | -19.5% | +71.9% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.